Target ID | Target Type | Target Name | Target Organism | Activity Type | Activity Relation | Value | Unit | Reference |
---|---|---|---|---|---|---|---|---|
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 210 | nM | 17302398 |
NPT3827 | Individual Protein | Pyrimidinergic receptor P2Y4 | Homo sapiens | EC50 | = | 130 | nM | 17302398 |
NPT1391 | Individual Protein | Pyrimidinergic receptor P2Y6 | Homo sapiens | EC50 | = | 20000 | nM | 17302398 |
NPT3825 | Individual Protein | Purinergic receptor P2Y1 | Homo sapiens | EC50 | > | 20000 | nM | 17011188 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 210 | nM | 18514530 |
NPT3827 | Individual Protein | Pyrimidinergic receptor P2Y4 | Homo sapiens | EC50 | = | 130 | nM | 18514530 |
NPT1391 | Individual Protein | Pyrimidinergic receptor P2Y6 | Homo sapiens | EC50 | = | 1160 | nM | 18514530 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 112 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 270000 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 179 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 94.5 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 394 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 572 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 419 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 620000 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 145 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 216 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 231 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | > | 300000 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | Ratio EC50 | = | 25 | 19419204 | |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 100 | nM | 20095577 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 60 | nM | 22107038 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC329277 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Natural Product ID |
---|---|---|
0.8969 | High Similarity | NPC73765 |
0.8969 | High Similarity | NPC283698 |
0.8866 | High Similarity | NPC36985 |
0.8866 | High Similarity | NPC17892 |
0.866 | High Similarity | NPC320249 |
0.866 | High Similarity | NPC322594 |
0.8557 | High Similarity | NPC324390 |
0.8491 | Intermediate Similarity | NPC149843 |
0.8491 | Intermediate Similarity | NPC155087 |
0.8218 | Intermediate Similarity | NPC317639 |
0.8144 | Intermediate Similarity | NPC89051 |
0.8144 | Intermediate Similarity | NPC43246 |
0.7941 | Intermediate Similarity | NPC318166 |
0.7941 | Intermediate Similarity | NPC324516 |
0.7835 | Intermediate Similarity | NPC106780 |
0.7745 | Intermediate Similarity | NPC327344 |
0.757 | Intermediate Similarity | NPC328914 |
0.7549 | Intermediate Similarity | NPC315063 |
0.7547 | Intermediate Similarity | NPC328779 |
0.7453 | Intermediate Similarity | NPC120887 |
0.7438 | Intermediate Similarity | NPC284651 |
0.7358 | Intermediate Similarity | NPC280946 |
0.7358 | Intermediate Similarity | NPC226769 |
0.7358 | Intermediate Similarity | NPC6166 |
0.7353 | Intermediate Similarity | NPC163352 |
0.7353 | Intermediate Similarity | NPC210456 |
0.729 | Intermediate Similarity | NPC90240 |
0.7264 | Intermediate Similarity | NPC329384 |
0.7157 | Intermediate Similarity | NPC325723 |
0.7059 | Intermediate Similarity | NPC112842 |
0.7059 | Intermediate Similarity | NPC71339 |
0.6887 | Remote Similarity | NPC171116 |
0.6869 | Remote Similarity | NPC329077 |
0.6698 | Remote Similarity | NPC62927 |
0.6698 | Remote Similarity | NPC190334 |
0.6693 | Remote Similarity | NPC315058 |
0.6538 | Remote Similarity | NPC313962 |
0.6471 | Remote Similarity | NPC325902 |
0.6415 | Remote Similarity | NPC229249 |
0.6222 | Remote Similarity | NPC318142 |
0.6036 | Remote Similarity | NPC328806 |
0.6031 | Remote Similarity | NPC325750 |
0.6 | Remote Similarity | NPC478024 |
0.5926 | Remote Similarity | NPC319753 |
0.5922 | Remote Similarity | NPC315806 |
0.5841 | Remote Similarity | NPC109188 |
0.5736 | Remote Similarity | NPC313813 |
0.5686 | Remote Similarity | NPC316244 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC329277 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Drug ID | Developmental Stage |
---|---|---|---|
1.0 | High Similarity | NPD3129 | Phase 3 |
0.9897 | High Similarity | NPD3128 | Phase 3 |
0.9151 | High Similarity | NPD3139 | Phase 3 |
0.9057 | High Similarity | NPD3138 | Phase 3 |
0.8969 | High Similarity | NPD9639 | Clinical (unspecified phase) |
0.8144 | Intermediate Similarity | NPD9580 | Clinical (unspecified phase) |
0.8144 | Intermediate Similarity | NPD9581 | Clinical (unspecified phase) |
0.7677 | Intermediate Similarity | NPD9557 | Clinical (unspecified phase) |
0.7642 | Intermediate Similarity | NPD5789 | Clinical (unspecified phase) |
0.757 | Intermediate Similarity | NPD1455 | Phase 3 |
0.757 | Intermediate Similarity | NPD1454 | Phase 3 |
0.75 | Intermediate Similarity | NPD1686 | Approved |
0.7476 | Intermediate Similarity | NPD9565 | Discontinued |
0.7273 | Intermediate Similarity | NPD9556 | Approved |
0.7241 | Intermediate Similarity | NPD7914 | Suspended |
0.7212 | Intermediate Similarity | NPD755 | Phase 3 |
0.72 | Intermediate Similarity | NPD9561 | Approved |
0.72 | Intermediate Similarity | NPD9560 | Approved |
0.7184 | Intermediate Similarity | NPD241 | Discontinued |
0.7129 | Intermediate Similarity | NPD9546 | Phase 2 |
0.71 | Intermediate Similarity | NPD9558 | Phase 3 |
0.708 | Intermediate Similarity | NPD6946 | Approved |
0.7064 | Intermediate Similarity | NPD502 | Approved |
0.7059 | Intermediate Similarity | NPD280 | Approved |
0.7059 | Intermediate Similarity | NPD9533 | Phase 2 |
0.7054 | Intermediate Similarity | NPD1061 | Clinical (unspecified phase) |
0.6923 | Remote Similarity | NPD240 | Phase 3 |
0.6923 | Remote Similarity | NPD170 | Approved |
0.6923 | Remote Similarity | NPD9562 | Discovery |
0.6917 | Remote Similarity | NPD7761 | Suspended |
0.6887 | Remote Similarity | NPD841 | Approved |
0.6818 | Remote Similarity | NPD762 | Discontinued |
0.6796 | Remote Similarity | NPD9559 | Phase 1 |
0.6796 | Remote Similarity | NPD9529 | Phase 1 |
0.6789 | Remote Similarity | NPD501 | Phase 1 |
0.6759 | Remote Similarity | NPD251 | Approved |
0.6759 | Remote Similarity | NPD6943 | Clinical (unspecified phase) |
0.6731 | Remote Similarity | NPD238 | Clinical (unspecified phase) |
0.6731 | Remote Similarity | NPD239 | Phase 2 |
0.6698 | Remote Similarity | NPD9602 | Phase 3 |
0.6698 | Remote Similarity | NPD9604 | Approved |
0.6698 | Remote Similarity | NPD9603 | Phase 3 |
0.6667 | Remote Similarity | NPD7756 | Clinical (unspecified phase) |
0.6637 | Remote Similarity | NPD223 | Clinical (unspecified phase) |
0.6606 | Remote Similarity | NPD9585 | Discontinued |
0.6542 | Remote Similarity | NPD1760 | Approved |
0.6522 | Remote Similarity | NPD7651 | Approved |
0.6452 | Remote Similarity | NPD7992 | Clinical (unspecified phase) |
0.6441 | Remote Similarity | NPD1385 | Discontinued |
0.6415 | Remote Similarity | NPD9601 | Approved |
0.6228 | Remote Similarity | NPD514 | Clinical (unspecified phase) |
0.6182 | Remote Similarity | NPD9553 | Approved |
0.6182 | Remote Similarity | NPD301 | Discontinued |
0.6182 | Remote Similarity | NPD9554 | Approved |
0.6148 | Remote Similarity | NPD284 | Phase 1 |
0.6134 | Remote Similarity | NPD4743 | Phase 2 |
0.6132 | Remote Similarity | NPD9600 | Approved |
0.6106 | Remote Similarity | NPD279 | Clinical (unspecified phase) |
0.6071 | Remote Similarity | NPD267 | Discontinued |
0.6053 | Remote Similarity | NPD215 | Discontinued |
0.6019 | Remote Similarity | NPD9572 | Clinical (unspecified phase) |
0.6 | Remote Similarity | NPD6948 | Phase 3 |
0.6 | Remote Similarity | NPD2633 | Phase 1 |
0.5983 | Remote Similarity | NPD192 | Phase 2 |
0.5968 | Remote Similarity | NPD1804 | Phase 2 |
0.5968 | Remote Similarity | NPD1805 | Phase 2 |
0.5935 | Remote Similarity | NPD6693 | Phase 3 |
0.5929 | Remote Similarity | NPD500 | Discontinued |
0.5926 | Remote Similarity | NPD2691 | Clinical (unspecified phase) |
0.5926 | Remote Similarity | NPD9573 | Phase 2 |
0.5922 | Remote Similarity | NPD9653 | Clinical (unspecified phase) |
0.5902 | Remote Similarity | NPD1428 | Phase 2 |
0.5888 | Remote Similarity | NPD9429 | Discontinued |
0.5841 | Remote Similarity | NPD1331 | Approved |
0.581 | Remote Similarity | NPD9407 | Approved |
0.5766 | Remote Similarity | NPD9555 | Phase 2 |
0.5714 | Remote Similarity | NPD3121 | Phase 2 |
0.5692 | Remote Similarity | NPD6936 | Clinical (unspecified phase) |
0.5692 | Remote Similarity | NPD6935 | Phase 3 |
0.5657 | Remote Similarity | NPD9504 | Approved |
0.5657 | Remote Similarity | NPD9503 | Approved |
0.5648 | Remote Similarity | NPD9427 | Approved |
PubChem CID   | 148197 |
ChEMBL   | CHEMBL221326 |
ZINC   |
Molecular Weight:   | 789.99 |
ALogP:   | -5.2592 |
MLogP:   | 0.03 |
XLogP:   | -8.32 |
# Rotatable Bonds:   | 24 |
Polar Surface Area:   | 439.77 |
# H-Bond Aceptor:   | 27 |
# H-Bond Donor:   | 10 |
# Rings:   | 4 |
# Heavy Atoms:   | 49 |